Personal information

Other IDs

ResearcherID: M-3691-2018

Activities

Collapse all

Employment (3)

ANOVA CRO s.r.o.: Brno, CZ

2023-04-01 to present | Statistician (Statistics)
Employment
Source: Self-asserted source
Lucie Nekvindová

Aixial s.r.o.: Brno, CZ

2022-08-01 to 2023-03-31 | Senior statistician (Statistics)
Employment
Source: Self-asserted source
Lucie Nekvindová

Institute of Biostatistics and Analyses, Ltd: Brno, CZ

2017 to 2022-07-31 | Data analyst (Data analysis)
Employment
Source: Self-asserted source
Lucie Nekvindová

Education and qualifications (2)

Charles University: Prague, CZ

2017 to 2022-06-30 | PhD (Institute of Rheumatology)
Education
Source: Self-asserted source
Lucie Nekvindová

Masaryk University: Brno, CZ

2012 to 2017 | Master of Science (Faculty of Science)
Education
Source: Self-asserted source
Lucie Nekvindová

Works (13)

Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry

Scandinavian Journal of Rheumatology
2025-03-04 | Journal article
DOI: 10.1080/03009742.2024.2381746
Contributors: Š Tichý; L Nekvindová; J Baranová; J Vencovský; K Pavelka; P Horák; J Závada
Source: check_circle
Crossref

Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

Arthritis & Rheumatology
2024-02-25 | Journal article
DOI: 10.1002/art.42758
Part of ISSN: 2326-5191
Part of ISSN: 2326-5205
Contributors: Pasoon Hellamand; Marleen G. H. van de Sande; Lykke M. Ørnbjerg; Thomas Klausch; Kari K. Eklund; Heikki Relas; Maria Jose Santos; Elsa Vieira‐Sousa; Anne Gitte Loft; Bente Glintborg et al.
Source: Self-asserted source
Lucie Nekvindová

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

2023-06-13 | Other
DOI: 10.1093/rheumatology/kead284
Contributors: Louise Linde; Lucie Nekvindová; Jirí Vencovský; Matija Tomšic; Michael John Nissen; Merih Birlik; Sukran Erten; Elsa Vieira-Sousa; Merete Lund Hetland; Anne Gitte Loft et al.
Source: check_circle
Crossref

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

Therapeutic Advances in Musculoskeletal Disease
2022-02 | Journal article
DOI: 10.1177/1759720x221081649
Part of ISSN: 1759-720X
Part of ISSN: 1759-7218
Source: Self-asserted source
Lucie Nekvindová

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

Annals of the Rheumatic Diseases
2021-06-03 | Journal article
DOI: 10.1136/annrheumdis-2021-220097
Part of ISSN: 0003-4967
Part of ISSN: 1468-2060
Source: Self-asserted source
Lucie Nekvindová

Real‐world 6 and 12‐month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries

Arthritis Care & Research
2021-01-18 | Journal article
DOI: 10.1002/acr.24560
Part of ISSN: 2151-464X
Part of ISSN: 2151-4658
Source: Self-asserted source
Lucie Nekvindová

Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

Arthritis Research & Therapy
2021-01-06 | Journal article
DOI: 10.1186/s13075-020-02393-8
Part of ISSN: 1478-6362
Source: Self-asserted source
Lucie Nekvindová

Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO‐CLLEAR Study by the Czech CLL Study Group

Hematological Oncology
2020-10 | Journal article
DOI: 10.1002/hon.2744
Part of ISSN: 0278-0232
Part of ISSN: 1099-1069
Source: Self-asserted source
Lucie Nekvindová

Switching First-Line Targeted Therapy After Not Reaching Low Disease Activity Within Six Months is Superior to Conservative Approach: A Propensity Score Matched Analysis From The ATTRA Registry

2020-09-17 | Other
DOI: 10.21203/rs.3.rs-76194/v1
Contributors: Lucie Nekvindova; Jiří Vencovský; Karel Pavelka; Pavel Horák; Zlatuše Křístková; Jakub Závada
Source: check_circle
Crossref

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Allergy
2020-08 | Journal article
DOI: 10.1111/all.14248
Contributors: Jakub Trizuljak; Wolfgang R. Sperr; Lucie Nekvindová; Hanneke O. Elberink; Karoline V. Gleixner; Aleksandra Gorska; Magdalena Lange; Karin Hartmann; Anja Illerhaus; Massimiliano Bonifacio et al.
Source: check_circle
Crossref

Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry

Expert Opinion on Biological Therapy
2020-02-01 | Journal article
DOI: 10.1080/14712598.2020.1694900
Contributors: Jan Tužil; Tomáš Mlčoch; Jitka Jirčíková; Jakub Závada; Lucie Nekvindová; Michal Svoboda; Michal Uher; Zlatuše Křístková; Jiří Vencovský; Karel Pavelka et al.
Source: check_circle
Crossref

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study

Rheumatology International
2019-03-03 | Journal article
DOI: 10.1007/s00296-018-4190-2
Contributors: Barbora Šumová; Lucie Andrés Cerezo; Lenka Szczuková; Lucie Nekvindová; Michal Uher; Hana Hulejová; Radka Moravcová; Mariam Grigorian; Karel Pavelka; Jiří Vencovský et al.
Source: check_circle
Crossref

Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.

Clinical and experimental rheumatology
2019-01-04 | Journal article
PMID: 30620295
Source: Self-asserted source
Lucie Nekvindová
How many people are using ORCID?